Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit...

Area of Science:

• Immunology
• Public Health
• Medical Diagnostics

Background:

• The International Patient Organisation for Primary Immunodeficiencies (IPOPI) convened its second Global Multi-Stakeholders' Summit to address critical challenges and opportunities in primary immunodeficiency (PID).
• The summit focused on three pivotal areas: personalizing immunoglobulin (Ig) therapy, enhancing pandemic preparedness for the PID community, and advancing PID diagnostics by 2030.

Framework:

• Exploring mechanistic insights and tailored Ig products to meet individual patient needs and local infectious disease risks.
• Assessing public health strategies for pandemic preparedness, including the critical threat of antibiotic shortages and antimicrobial resistance for vulnerable populations.
• Addressing global diagnostic disparities and integrating patient-reported outcomes and artificial intelligence for more precise and accessible PID diagnosis.

Implementation:

• Clinician-scientists, patient advocates, and stakeholders collaborated to identify actionable strategies for improving Ig therapy and patient care.
• Emphasizing the necessity of including PID patients and other vulnerable groups in crisis and care management planning.
• Discussing the integration of novel diagnostic approaches, including AI, to overcome current limitations in PID detection.

Implications:

• The summit's outcomes provide crucial insights for future strategies in PID management and patient care.
• Fostering collaborative efforts among diverse stakeholders is essential for proactively addressing the multifaceted challenges within the global PID community.
• Recommendations aim to improve treatment efficacy, patient safety during health crises, and diagnostic accuracy for primary immunodeficiencies.